Literature DB >> 17565025

Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.

David B Badesch1, Steven H Abman, Gerald Simonneau, Lewis J Rubin, Vallerie V McLaughlin.   

Abstract

A consensus panel convened by the American College of Chest Physicians developed guidelines for the treatment of pulmonary arterial hypertension (PAH) that were published in 2004. Subsequently, several important clinical trials have been published, and new treatments have received regulatory approval. In addition, add-on and combination therapy are being explored, which promise to open new therapeutic avenues. This article, taking into consideration studies published prior to September 1, 2006, provides an update to the previously published guidelines. The original guidelines have been summarized, a discussion of new studies has been added, and the treatment algorithm has been revised to take into account recent developments in therapy. This update provides evidence-based treatment recommendations for physicians involved in the care of patients with PAH. Due to the complexity of the diagnostic evaluation required and the treatment options available, referral of patients with PAH to a specialized center continues to be strongly recommended.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565025     DOI: 10.1378/chest.06-2674

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  120 in total

1.  Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing.

Authors:  Douglas L Prisco; Anthony L Sica; Arunabh Talwar; Mangala Narasimhan; Kennedy Omonuwa; Babak Hakimisefat; Sophy Dedopoulos; Nawid Shakir; Harly Greenberg
Journal:  Sleep Breath       Date:  2010-10-07       Impact factor: 2.816

2.  Early recognition and management of pulmonary arterial hypertension: a case for profiling.

Authors:  Kalyan Kosuri; Ghulam Saydain
Journal:  Oman Med J       Date:  2012-01

Review 3.  Targeted oral therapies in the treatment of pulmonary arterial hypertension.

Authors:  Zeenat Safdar
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

5.  Pulmonary arterial hypertension.

Authors:  Sheng Chin Wu; Sergio Caravita; Elisabetta Lisi; Simona Pierini; Viola Dadone; Sarah E Todd; Francesco Gentile; Maria Beatrice Secchi
Journal:  Intern Emerg Med       Date:  2009-12       Impact factor: 3.397

6.  Noninvasive assessment of right heart function and hemodynamics during exercise in patients with pulmonary arterial hypertension.

Authors:  Michelle L Freeman; Carolyn Landolfo; Robert E Safford; Cesar A Keller; Michael G Heckman; Charles D Burger
Journal:  South Med J       Date:  2013-02       Impact factor: 0.954

7.  Impact of calcium-channel blockers on right heart function in a controlled model of chronic pulmonary hypertension.

Authors:  Andreas Zierer; Rochus K Voeller; Spencer J Melby; Paul Steendijk; Marc R Moon
Journal:  Eur J Anaesthesiol       Date:  2009-03       Impact factor: 4.330

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

9.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Authors:  Muhammad Shahzeb Khan; Muhammad Shariq Usman; Tariq Jamal Siddiqi; Safi U Khan; M Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Richard A Krasuski; Raymond L Benza; Jonathan D Rich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-09

Review 10.  Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension.

Authors:  Shuyan Gu; Huimei Hu; Hengjin Dong
Journal:  Pharmacoeconomics       Date:  2016-08       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.